Fosnetupitant

Summary

Fosnetupitant (CHEMBL3989917) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 688.6 Da · C31H35F6N4O5P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989917
Name	Fosnetupitant
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71544786
Molecular formula	C31H35F6N4O5P
Molecular weight	688.6
InChIKey	HZIYEEMJNBKMJH-UHFFFAOYSA-N

SMILES: CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC[N+](CC4)(C)COP(=O)(O)[O-]

IUPAC name: [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)-2-pyridinyl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate

Also known as: Fosnetupitant, FOSNETUPITANT

Parent form; salt/anhydrous children: CHEMBL3989919

Patent coverage: 41 distinct patent families (83 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 80 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03403712	PHASE3	COMPLETED	A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).